Valuation: LivaNova PLC

Market Cap 4.45B 3.87B 3.59B 3.31B 6.24B 425B 6.35B 42.52B 16.65B 211B 16.72B 16.35B 710B P/E 2026 *
29.1x
P/E 2027 * 25.2x
Enterprise Value 4.45B 3.87B 3.59B 3.31B 6.24B 425B 6.35B 42.52B 16.65B 211B 16.72B 16.35B 710B EV / Sales 2026 *
2.95x
EV / Sales 2027 * 2.76x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 01/03/2024
Director of Finance/CFO 56 31/10/2020
Investor Relations Contact - 01/08/2022
Director TitleAgeSince
Director/Board Member 69 19/10/2015
Chairman 74 09/06/2021
Director/Board Member 62 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.64% - - 4.45B
-2.21%+4.82%-17.85%-6.32% 183B
-2.09%+4.51%-6.47%-2.88% 110B
-2.00%+2.35%+7.00%+67.36% 60.75B
+4.15%+1.22%+29.61%+50.39% 50.01B
-1.75%+8.16%-8.86%-40.98% 45.59B
-2.40%+3.96% - - 33.08B
-0.80%+5.76%-16.30%-43.69% 28.76B
+0.63%-4.47%+36.27%-7.08% 23.9B
-1.54%+9.77%+0.85%+0.51% 22.53B
Average -0.79%+4.36%+3.03%+2.17% 61.9B
Weighted average by Cap. -1.32%+5.48%-3.92%+3.55%

Financials

2026 *2027 *
Net sales 1.51B 1.31B 1.22B 1.12B 2.11B 144B 2.15B 14.4B 5.64B 71.5B 5.66B 5.54B 240B 1.61B 1.4B 1.3B 1.2B 2.26B 154B 2.3B 15.42B 6.04B 76.55B 6.06B 5.93B 257B
Net income 148M 129M 120M 110M 208M 14.17B 212M 1.42B 555M 7.04B 557M 545M 23.66B 179M 156M 145M 133M 251M 17.13B 256M 1.71B 671M 8.51B 674M 659M 28.61B
Net Debt - -
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA